Effect of Botulinum Toxin Injection Guided by Ultrasound Combined With Balloon Localization on Cricopharyngeal Achalasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-01

Study Completion Date

2024-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

cricopharyngeal achalasia refers to incomplete or non-open functional opening of the cricopharyngeal muscle, and after repeated swallowing of food, it still cannot pass through the cricopharyngeal muscle, remaining in the epiglottic valley and the piriform fossa, and even regurgitated into the nasal cavity . Neurogenic diseases, myogenic diseases and head and neck tumors are the common causes. Patients with chronic underfeeding lead to malnutrition, reduced quality of life, affecting the outcome of the disease. At present, the treatment measures for cricopharyngeal achalasia at home and abroad include balloon dilation technique, surgical incision, botulinum toxin injection. The dilation of the balloon is easy to cause mucosal edema and damage. Local infection, massive hemorrhage, local nerve injury and other complications often occur in cricopharyngotomy. Botulinum toxin injection relieves muscle spasms and is now widely used to treat dystonia. Common injection localization methods include CT, ultrasound, electromyography and endoscopy. Ultrasound-guided injection is a new technique of visualization, simple and non-radiation injection guidance, which can observe the injection process and drug injection position in real time. Fixation with a balloon can further improve the accuracy of the injection. In this study, botulinum toxin was injected into the cricopharyngeal muscle by ultrasound combined with balloon.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ultrasound-guided Botulinum Toxin Injection on Cricopharyngeal Muscle Dysfunction

NCT06271395

Cricopharyngeal Achalasia

RECRUITING NA

Ultrasound-guided Botulinum Toxin Injection on Cricopharyngeal Muscle Dysfunction

NCT06328556

Cricopharyngeal Achalasia

NOT_YET_RECRUITING NA

Onabotulinum Toxin A (Botox) in the Treatment of Transfer Dysphagia

NCT04695600

Transfer Dysphagia Oropharyngeal Dysphagia Cricopharyngeus Muscle Dysfunction +1 more

UNKNOWN PHASE2/PHASE3

Randomized Study of Botulinum Toxin Type A for Achalasia

NCT00004416

Esophageal Achalasia

COMPLETED NA

Effect of Botulinum Toxin Injection Into Upper Esophageal Sphincter in Patients With Medullary Infarction

NCT06196606

Brain Stem Infarctions Dysphagia, Oropharyngeal Dysphagia, Esophageal

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Under the ultrasound combined with balloon fixation, two injection sites were selected from the left upper esophageal sphincter, and 30U was injected respectively, and one injection site was selected from the right side, and 30U was injected. In addition, the patient also received routine swallowing training once a day for 30 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cricopharyngeal Achalasia Dysphagia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental group

Botulinum toxin type A for injection (Hengli National Drug approval number S10970037) 100U, diluted with

1 ml.9% sodium chloride solution for reserve use.Each patient was injected with 90U

Group Type EXPERIMENTAL

Botulinum toxin type A for injection

Intervention Type DRUG

Botulinum toxin was injected into the upper esophageal sphincter of each patient

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Botulinum toxin type A for injection

Botulinum toxin was injected into the upper esophageal sphincter of each patient

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Botulinum toxin type A for injection (Hengli National Drug approval number S10970037)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The videofluoroscopic swallowing study (VFSS) confirmed that the cricopharyngeal muscle was not open/closed
* Patients with no significant improvement in swallowing function after more than 2 weeks of standardized rehabilitation therapy (FOIS unchanged or decreased)
* In the presence of swallowing initiation, VFSS is seen in swallowing with an upward motion of the hyoid greater than half the height of the C3 cone
* Vital signs stable, conscious, treatment cooperative
* The patient himself or his family members sign the written informed consent voluntarily

Exclusion Criteria

* Patients with severe cognitive impairment, mental illness, and severe cardiopulmonary disease
* The structure of the throat is abnormal
* Malignant tumor patient
* Infection or wound at the injection site
* People allergic to botulinum toxin
* Bleeding tendency and coagulation disorder

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No